---
title: "CRISPR Comes of Age, But Wall Street Isn't Buying the Revolution"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295518134.md"
description: "Gene editing is finally delivering real clinical breakthroughs in 2026, with Intellia nearing commercialization and Editas successfully pivoting. Yet, as science wins, investor enthusiasm remains stubbornly muted in a brutal reality check."
datetime: "2026-08-11T10:11:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295518134.md)
  - [en](https://longbridge.com/en/news/295518134.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295518134.md)
generator: "portal-rs"
---

# CRISPR Comes of Age, But Wall Street Isn't Buying the Revolution

The CRISPR revolution was supposed to be easy magic. It isn't. In 2026, the science is actually working, but the business of gene editing has become a brutal, capital-intensive slog. Wall Street wanted a quick tech-like disruption; instead, they are getting a masterclass in pharmaceutical reality.

Take Intellia Therapeutics (NTLA.US). In April, they delivered a legitimate milestone: Phase 3 data showing their in vivo therapy Lonvo-z slashed hereditary angioedema attacks by 87%. They are prepping for a late-2026 FDA filing and a 2027 commercial launch. The science is undeniably brilliant. The reward? Analysts immediately slashed their revenue estimates after missing Q2 targets, obsessing over a drop in collaboration revenue to $7.7 million. Intellia is sitting on a $628 million war chest to last until 2028, but the market is entirely missing the forest for the trees.

Then there is Editas Medicine (EDIT.US), the pioneer that had to swallow its pride and execute a hard pivot. After wisely killing its reni-cel program in 2024, Editas is betting the house on EDIT-401 for high cholesterol. Preclinical data shows a massive 90% drop in LDL-C, and they are dragging this into Phase 1/2 trials in Australia this August. To buy time for this second act, they engineered a $319.4 million public offering in May. They managed to shrink their Q2 net loss to $18.2 million and extended their runway to late 2028.

The bottom line? The gene-editing era is no longer a sci-fi fantasy pitch deck. The therapies are arriving, and they are saving lives. But the market's patience is already gone, proving once again that revolutionary biology and quarterly earnings models are a terrible match.

### Related Stocks

- [EDIT.US](https://longbridge.com/en/quote/EDIT.US.md)
- [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md)

## Related News & Research

- [Intellia Q2 2026 Earnings: Lonvo-z Moves Toward a BLA](https://longbridge.com/en/news/295103160.md)
- [Intellia grants inducement RSUs for 38,200 shares to eight new employees](https://longbridge.com/en/news/295272227.md)
- [Oil prices mixed; may be buoyed amid deadlock in US.-Iran talks](https://longbridge.com/en/news/296041997.md)
- [Energy Department eyes American oil comeback](https://longbridge.com/en/news/296139041.md)
- [Cuba seized their mines in 1960. Now two American bidders want them back](https://longbridge.com/en/news/296029199.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**